Sox2 plays critical roles in cell fate specification during development and in stem cell formation; however, its role in postmitotic cells is largely unknown. Sox2 is highly expressed in supporting cells (SCs) of the postnatal mammalian auditory sensory epithelium, which unlike non-mammalian vertebrates remains quiescent even after sensory hair cell damage. Here, we induced the ablation of Sox2, specifically in SCs at three different postnatal ages (neonatal, juvenile and adult) in mice. Kip1 expression is an effective approach to inducing proliferation of neonatal auditory IPCs, an initial but necessary step toward restoring hearing in mammals.
Introduction
The mouse cochlear sensory epithelium, also referred to as the organ of Corti, contains one row of inner hair cells (IHCs); three rows of outer hair cells (OHCs) along with adjacent supporting cell (SC) subtypes such as inner pillar cells (IPCs), outer pillar cells (OPCs) and Deiters' cells (DCs) whose nuclei reside at the level below the hair cell (HC) bodies. In the prosensory phase of cochlear development, prosensory progenitors are specified and continue proliferating until p27 Kip1 , a Cip/Kip family cell cycle inhibitor, is turned on in an apical to basal gradient between embryonic day 12.5 (E12.5) and E14.5 . After cell cycle exit, these progenitors differentiate into either HCs or SCs in a process mediated by Notch1 signaling (Lanford et al., 1999; Liu et al., 2012a) and Atoh1 (Bermingham et al., 1999) .
Sox2 can both regulate the cochlear prosensory area formation (Kiernan et al., 2005) and mediate the cell fate of these progenitors by antagonizing Atoh1 (Dabdoub et al., 2008) . As differentiation advances, Sox2 and p27
Kip1 are gradually limited to SCs and become undetectable in HCs by birth. Although the details are unknown, p27
Kip1 has been shown to keep postnatal SCs quiescent (Ono et al., 2009; Oesterle et al., 2011) . However, the roles of Sox2 in postnatal SCs remain unclear.
When auditory HCs are damaged in non-mammalian vertebrates such as birds, fish and amphibians, SCs proliferate and trans-differentiate into HCs (Stone and Cotanche, 2007; Brigande and Heller, 2009 ). Unfortunately, mammals are unable to regenerate auditory HCs after damage and SCs are tightly kept quiescent. Interestingly, SCs isolated from neonatal mice can spontaneously downregulate p27 Kip1 , proliferate and differentiate into HC-like cells when cultured in vitro (White et al., 2006) . Although the mechanism remains elusive, this finding not only provides a promising approach to regenerate auditory HCs in mammals, but also highlights the importance of understanding how the quiescent state of postnatal SCs is maintained and identifying upstream regulator(s) of p27 Kip1 . Using the tamoxifen-inducible CreER/loxP system, we deleted Sox2 in cochlear SCs at different postnatal ages. We found that Sox2-null IPCs lost expression of p27 Kip1 and proliferated. This proliferative capacity declined with maturation. In addition, when p27
Kip1 was deleted, IPCs proliferated but maintained expression of Sox2. Furthermore, in vitro studies illustrated that Sox2 physically binds to the promoter of p27 Kip1 . Together, our data show that Sox2 is a key regulator in maintaining p27 Kip1 expression and quiescence in IPCs.
Materials and Methods

Mice and tamoxifen treatment. Sox2 loxP/loxP , Prox1
CreER/ϩ , p27 loxP/loxP , Fgfr3 iCreERϩ , and CAG-EGFPϩ reporter mice were generated as described previously (Chien et al., 2006; Nakamura et al., 2006; Srinivasan et al., 2007; Miyagi et al., 2008; Young et al., 2010) . Rosa26-EYFP loxP/ϩ (stock # 006148) and Rosa26-CAG-tdTomato loxP/ϩ (Ai14, stock # 007914) reporter mice were obtained from The Jackson Laboratory. Neonatal or juvenile mice were given tamoxifen (3 mg/40 g) at postnatal day 0 (P0) and P1 (24 h interval), or P6 and P7 (24 h interval). Adult mice were given tamoxifen (9 mg/40 g) at P30 once only. Mice of either sex were used for all experiments. All animal work conducted during the course of this study was approved by the Institutional Animal Care and Use Committee at St. Jude Children's Research Hospital and was performed according to NIH guidelines.
Tissue preparation, immunofluorescence, and analysis. After fixing in 4% PFA overnight, whole-mount cochlear tissues were divided into 3 parts. After scanning each part with a confocal microscope (Zeiss LSM 700) with a 10ϫ lens, the total length of cochleae was measured. Then, each cochlea was divided into 3 turns of equal length (apical, middle, and basal).
The following primary antibodies were used for immunostaining following protocols that were described previously Yu et al., 2010) : anti-myosin VI (1:200, 25-6791, Proteus Bioscience), anti-myosin VIIa (1:200, 25-6790, Proteus Bioscience), anti-BrdU (1:50, B35130/B35131/B35133, Invitrogen), antiProx1 (1:500, AB5475, Millipore), anti-calbindin (1:500, AB1778, Millipore), anti-p75 NGFR (1: 1000, AB1554, Millipore), anti-GFP (1:1000, ab13970, Abcam), anti-p27 Kip1 (1:500, 610242, BD Transduction Laboratories), anti-Sox2 (1: 1000, sc-17320, Santa Cruz Biotechnology) and anti-phospho-histone 3 (pH3) (1:20, 9708, Cell Signaling Technology). All secondary antibodies were purchased from Invitrogen and used as 1:1000 dilutions.
For p27 Kip1 whole-mount staining, an antigen retrieval process (H-3300, Vector Laboratories) was performed, followed by the Tyramide Signal Amplification Kit (T20912, Invitrogen). For cell death measurements, TUNEL staining was performed with the In Situ Cell Death Detection kit, Fluorescein, or TMR Red (11684795910 or 12156792910, Roche Applied Science) following the manufacturer's instructions. EdU (5-ethynyl-2Ј-deoxyuridine) labeling was performed using the Click-iT EdU labeling kit (Invitrogen, C10337/C10338/C10340) following the manufacturer's instructions. Luciferase assays. Plasmids containing the p27 Kip1 promoter driving luciferase and the empty luciferase control were obtained from Dr. Toshiyuki Sakai (Kyoto Prefectural University of Medicine, Kyoto, Japan). LacZ, E2F1, and Sox2 expression vectors were obtained from Addgene (plasmid 18816, 10736, and 13459). Luciferase and ␤-galactosidase activity were assayed by the Applied Biosystems DualLight kit and quantitated on a Glomax Multiϩ plate reader (Promega). Plasmids were cotransfected into ϳ10,000 MEF (mouse embryonic fibroblast), HeLa, or HEK (human embryonic kidney) cells using Lipofectamine LTX (Invitrogen), following the manufacturer's protocol (7:1 LTX/DNA ratio). HEK and immortalized MEF cells were obtained from Dr. M. Kundu (St. Jude's Children's Research Hospital, Memphis, TN). HeLa cells were obtained from ATCC.
Chromatin immunoprecipitation assay. Chromatin immunoprecipitation (ChIP) was performed on MEF cells which had been transfected with both the p27
Kip1
-luciferase vector and Sox2 using the Simple ChIP Magnetic kit (Cell Signaling Technology). DNA was first precleared with overnight incubation with the IgG antibody followed by 30 min incubation with the magnetic beads, which were discarded. Next DNA/protein complexes were immunoprecipitated using 2 l of ChIP-formulated Sox2 antibody (Cell Signaling Technology, 5024) . DNA was liberated, purified and then quantified by qPCR using SYBR Green (Bio-Rad) on an Eppendorf RealPlex 2 . A total of 9 sets of primer pairs covering ϳ2 kb of contiguous p27 kip1 promoter and 1 nonspecific primer pair located downstream of the luciferase open iCreERϩ ; Sox2 ϩ/ϩ control (A-C) and Fgfr3 iCreERϩ ; Sox2 loxP/loxP experimental (D-F ) samples given tamoxifen at P0 and P1 at the HC layer (A, D) and SC layer (B, E). C and F are artificial cross-section images in the YZ plane. Arrows in E and F point to the same EdUϩ/Sox2-negative IPC. Dashed lines in C and F represent the basilar membrane. G-H, Control (G) and experimental (H-H) samples were stained with myosin VI, EdU, and BrdU. G and H are images taken at the HC layer, and H at the SC layer. Arrow in H shows an EdUϩ/BrdUϩ IPC. I, Quantification of EdUϩ IPCs in the entire cochlea of experimental samples given TMX at P0 and P1, EdU at P2, and analyzed 6 h later or at P4.**p Ͻ 0.01 (n ϭ 3). Scale bars, 20 m. 
Results
Neonatal IPCs proliferate and generate daughter cells after deletion of Sox2
In the postnatal cochlea, Sox2 is highly expressed in SCs inside the organ of Corti, in cells of the greater epithelial ridge and in Hensen's cells which are lateral to the organ of Corti (Liu et al., 2012c) . To determine the roles of Sox2 in IPCs, OPCs and DCs, we first tried to breed Sox2 loxP/loxP mice with our previously characterized Prox1
CreER/ϩ line whose Cre activity is restricted to pillar cells (PCs) and DCs when tamoxifen is given at P0 and P1 (Yu et al., 2010) . However, for reasons unknown, it was very difficult to get Prox1
CreERϩ ;Sox2 loxP/loxP mice by breeding both lines. Therefore, we instead characterized the Fgfr3 iCreERϩ transgenic mouse (Young et al., 2010) . When tamoxifen was given at P0 and P1, inside the organ of Corti, the iCre activity of Fgfr3 iCreERϩ is primarily restricted into IPCs, OPCs, and DCs (Cox et al., 2012) . Of note, iCreϩ OHCs, Hensen's cells or Claudius cells were also observed, but iCreϩ IHCs and inner phalangeal cells (IPHs) were never observed. Although Cre activity of Fgfr3 iCreERϩ mice was not entirely specific to SCs, it was suitable for our study because Sox2 is normally undetectable in all postnatal HCs (Liu et al., 2012b ϩ/ϩ mice (control group). Both groups were given tamoxifen at P0 and P1, EdU once at P2 and analyzed 6 h later (Fig. 1A-F) . While Sox2 was maintained in all IPCs, OPCs, and DCs in control mice (Fig. 1B) , Sox2-negative IPCs, OPCs, and DCs were found in all cochlear turns of experimental mice (Fig. 1E ). There was no significant difference in the length of the cochlea between control (5700 Ϯ 200 m) and experimental groups (5800 Ϯ 185 m) by P2 when the cochlea has reached its final length (Morsli et al., 1998) . Control mice had no EdUϩ SCs inside the organ of Corti (Fig. 1B) , while EdUϩ mesenchymal cells were observed below the basilar membrane (Fig. 1C , dashed line) which serve as an internal positive control for EdU staining. In contrast, scanning the entire cochlea by confocal microscopy revealed 86 Ϯ 11 EdUϩ cells (n ϭ 3) (all Sox2-negative) in each experimental mouse: ϳ81% were in apical turns and ϳ19% in middle turns. Interestingly, all EdUϩ cells were IPCs, defined by their unique oblong nuclei and location (Fig. 1E, F, arrows) . This implies that Sox2 ablation at P0 and P1 leads to S phase reentry of IPCs only.
We also found EdUϩ/pH3ϩ IPCs (data not shown), indicating Sox2-negative IPCs entered M phase. To further determine whether EdUϩ IPCs could complete the cell cycle and generate new daughter cells, EdU was given once at P2, followed by 5 injections of BrdU (at 2 h intervals) at P4 and analyzed 2 h later after the last BrdU injection , and EdU in cochlear samples from experimental mice. Arrows point to the same EdUϩ/ Sox2-negative/p27 Kip1 -negative IPC. Arrowheads point to the same Sox2-negative IPC that maintained faint expression of p27
Kip1 and was EdU-negative, which is also visualized at a higher magnification (inset in Bٟ). C-Dٟ, Double labeling of Sox2 and Prox1 in control ( Fig. 1G,HЈ) . Quantification of the entire cochlea revealed 3 types of IPCs: EdUϩ only, BrdUϩ only and EdUϩ/BrdUϩ. The presence of EdUϩ/BrdUϩ IPCs (45 Ϯ 5 cells, n ϭ 3) demonstrated that proliferating IPCs that incorporated EdU at P2 gave birth to daughter cells, which reentered S phase and incorporated BrdU at P4 (Fig.  1HЈ , arrow). Consistently, there were significantly more EdUϩ IPCs (both single EdUϩ and EdUϩ/BrdUϩ) at P4 than at P2 (Fig. 1I ). In addition, 90% of EdUϩ/BrdUϩ IPCs were distributed in apical turns and 10% in middle turns, while 85% of IPCs that were only EdUϩ were in apical turns and 15% in middle turns. Interestingly, 80% of IPCs that were only BrdUϩ were in apical turns, 17% in middle turns and 3% in basal turns. This suggests that Sox2-negative IPCs in basal turns began to reenter S phase at P4, 2 d later than IPCs in apical and middle turns.
Next, we probed the mechanism underlying the apical-to-basal gradient numbers of EdUϩ IPCs and the delay in proliferation of IPCs in basal turns. While ϳ55% of IPCs were Sox2-negative throughout the entire cochlea at P2, ϳ23% of IPCs were p27 Kip1 -negative in apical turns, ϳ2.5% of IPCs were p27 Kip1 -negative in middle turns and all IPCs retained p27
Kip1 expression in basal turns ( Fig. 2A ). This suggests that repression of p27
Kip1 following Sox2 deletion determines the proliferative capacity of IPCs and is supported by the presence of Sox2-negative/p27
Kip1 -negative/EdUϩ IPCs in apical, middle and basal turns at P4 arrows) . In addition, all EdUϩ IPCs were Sox2-negative/p27 Kip1 -negative. Note that there were Sox2-negative/EdUnegative IPCs where faint, but detectable, p27
Kip1 expression was present ( Fig. 2B -Bٞ, arrowheads). We could not determine the percentage of Sox2-negative or p27
Kip1 -negative IPCs in each turn at P4 or older ages primarily because newly generated daughter cells were also Sox2-negative/p27
Kip1 -negative and were different from original Sox2-negative/ p27
Kip1 -negative IPCs obtained by Cremediated recombination (Fig. 2 A) . Moreover, we could not determine whether Sox2-negative/p27
Kip1 ϩ IPCs later become p27
Kip1 -negative. In contrast, all OPCs and DCs (either Sox2ϩ or Sox2-negative) retained expression of p27
Kip1 at P4 (Fig. 2 B- Kip1 expression is maintained.
Daughter cells born from neonatal proliferating IPCs maintain the SC fate
In control mice, Prox1 is expressed in neonatal IPCs, OPCs, and DCs ( Fig. 2C-Cٞ) ; thus, we used Prox1 as a marker to define SC fate. Prox1 expression was maintained in all Sox2-negative IPCs, OPCs, and DCs at P4 (Fig. 2 D-Dٞ) . We did not analyze samples at older ages, because Prox1 is normally downregulated with age (Bermingham-McDonogh et al., 2006) . Nonetheless, our results suggest that Sox2 is not required to maintain Prox1 expression and Sox2-null SCs maintain their intrinsic cell fate until P4. In addition, there were no EdUϩ (or BrdUϩ)/myosin VIϩ cells or extra HCs in cochlear samples analyzed at P2 and P4 (Fig. 1) . This observation not only verifies our assumption that deletion of Sox2 in a few iCreϩ OHCs at P0 and P1 does not result in a detectable phenotype, but also suggests that there is no cell fate conversion from proliferative IPCs to HCs by P4 when Sox2 is deleted.
Juvenile IPCs reenter S phase and M phase but do not proliferate after deletion of Sox2
Cochlear development significantly advances within the first week after birth. Therefore, we deleted Sox2 in SCs at P6 and P7 (defined as juvenile SCs) to determine whether they still need Sox2 to remain quiescent. When tamoxifen was given at P6 and P7, inside the organ of Corti, iCre activity of Fgfr3 iCreERϩ were present in almost all IPCs, OPCs, and DCs (Cox et al., 2012) . Again, only a few iCreϩ cells were OHCs, Hensen's cells and Claudius cells. Kip1 -negative IPCs at P8 in the entire cochlea of experimental mice. E-Eٟ, Experimental samples were triple stained with Sox2, p27
Kip1 , and EdU. Arrows point to the same EdUϩ/Sox2-negative/p27 Kip1 -negative IPC. Arrowheads point to the same Sox2-negative IPC that maintained expression of p27
Kip1 and was EdU-negative. IPHs maintained normal Sox2 expression and were EdU-negative. Scale bars, 20 m.
Similar to the experimental design for neonatal ages, we used Fgfr3 iCreERϩ ; Sox2 loxP/loxP mice as the experimental group and Fgfr3 iCreERϩ ; Sox2 ϩ/ϩ mice as the control group. Both groups were treated with tamoxifen once a day at P6 and P7, EdU at P8 and analyzed 6 h later. Sox2 was expressed normally in IPCs, OPCs, and DCs in control mice (Fig. 3A-AЉ ), but lost in many IPCs, OPCs, and DCs in experimental mice (Fig. 3B-BЉ) . Consistently, no EdUϩ cells were observed inside the organ of Corti of control mice (Fig. 3A-AЉ) . In contrast, scanning of the entire cochlea of experimental mice revealed 45 Ϯ 12 (n ϭ 3) EdUϩ cells (all Sox2-negative) (Fig. 3B-BЉ) . All EdUϩ cells were IPCs, which were defined primarily according to their location and the unique structure of organ of Corti at P8 (Fig. 3C ). These results demonstrate that only Sox2-negative IPCs reenter S phase of the cell cycle. Among EdUϩ IPCs, 34.3% were distributed in apical turns, 37.2% in middle turns and 28.5% in basal turns. These numbers did not display the apical-to-basal gradient seen when Sox2 was deleted at P0 and P1. Consistently, there was no longer an apical-to-basal gradient of Sox2-negative/p27
Kip1 -negative IPCs at P8 (Fig. 3D) . It might be due to the overall lower level of p27
Kip1 at P6/7 than P0/1, thus a shorter time delay between Sox2 deletion and degradation of the endogenous p27
Kip1 below the detecting level. In addition, almost all IPCs lost Sox2 expression by P8 (Fig. 3D ) and all EdUϩ IPCs were p27 Kip1 -negative/Sox2-negative (Fig. 3E-Eٞ, arrows) . Again, Sox2-negative/p27 Kip1 ϩ IPCs were observed (Fig. 3E-Eٞ, arrowheads) . Both Sox2ϩ and Sox2-negative OPCs (Fig. 3E-Eٞ) and DCs continued to express p27 Kip1 , and we never observed EdU incorporation in these cell types.
We also found limited EdUϩ/pH3ϩ/Sox2-negative IPCs at P8 (8 Ϯ 2 in the whole cochlea, n ϭ 3) (Fig. 4A-BЉ) , indicating that at least some Sox2-negative IPCs enter M phase of the cell cycle. However, EdUϩ/BrdUϩ IPCs were not detected when EdU was given once at P8 and BrdU was given 5 times (at 2 h intervals) at P10 (Fig.  4C-DЈ) . In support, when EdU was given once at P8, there was no difference in the total number of EdUϩ IPCs between P8 and P10 (Fig. 4E) . These results suggest that Sox2-negative IPCs cannot complete the cell cycle and no new daughter cells were generated. Because we did not observe cells that were arrested at late M phase (or binucleated cells) at P10, the mitotic cells likely died between P8 and P10, as in the case of Rb Ϫ/Ϫ HCs that cannot complete mitosis (Weber et al., 2008) . However, we cannot rule out the possibility that some Sox2-negative IPCs do divide once and the daughter cells die immediately. In addition, when BrdU was injected 5 times (at 2 h intervals) at P10, only 5 Ϯ 2 (n ϭ 3) BrdUϩ IPCs were found in the whole cochlea, further supporting the notion that most, if not all, Sox2-negative IPCs became quiescent by P10. We performed lineage tracing experiments to determine whether these Sox2-negative SCs maintained a SC fate or switched to a HC fate. We could no longer use Prox1 to define SC fate as we did with neonatal ages (Fig. 2C-Dٞ) , because Prox1 is rapidly downregulated in SCs within the first week after birth, especially in IPCs (Bermingham-McDonogh et al., 2006) . Fgfr3 iCreERϩ ; Sox2 loxP/loxP ; CAG-EGFPϩ mice were used as the experimental group and Fgfr3 iCreERϩ ; Sox2 ϩ/ϩ ; CAG-EGFPϩ as the control group. BrdU was given once a day from P8 to P16 and samples were analyzed at P17. Our standard to define a HC fate (if converted from proliferating IPCs) was the presence of BrdUϩ/ EGFPϩ/calbindinϩ cells (Fig. 4 F) . We did not find such triplepositive cells, and all BrdUϩ/EGFPϩ cells did not express the HC marker calbindin (Fig. 4G-Hٞ) . Finally, consistent with the observation that iCre activity in Fgfr3 iCreERϩ mice was present in limited number of endogenous OHCs (Cox et al., 2012 ), a few EGFPϩ/calbindinϩ cells (endogenous HCs with iCre activity) were found in the experimental group. However, the number of EGFPϩ/calbindinϩ cells was similar between the experimental and control groups, suggesting that Sox2-negative OPCs and DCs also did not change fate to become HCs.
Sox2 deletion in adult IPCs causes limited cell cycle reentry without switching cell fate
Sox2 expression is maintained in adult SCs (Hume et al., 2007) . To study the role of Sox2 at adult ages, we deleted Sox2 in SCs at P30. When tamoxifen was given at P30, iCre activity were exclusively in SCs (Liu et al., 2012c mice to take advantage of their specific Cre activity in PCs and DCs (Yu et al., 2010) . Both groups were given tamoxifen once a day at P0 and P1, EdU at P4 and analyzed 6 h later. p27
Kip1 was expressed normally in control mice (Fig. 5 A, AЈ) , while many PCs and DCs in experimental mice lost p27
Kip1 expression (Fig. 5 B, BЈ) . Consistently, while no EdUϩ cells were found inside the organ of Corti in control mice (Fig. 5C ), EdUϩ cells were present in experimental mice (Fig. 5D) . We focused on the apical turn where Cre activity was the highest (Yu et al., 2010) . Strikingly, all EdUϩ cells were either IPCs or OPCs (Fig. 5 D, EЉ) and were p27
Kip1 -negative (Fig. 5E-EЉ) . Because of the low Cre activity of Prox1
CreER/ϩ , the number of EdUϩ PCs was limited. Since multiple EdU injections are lethal to neonates, we performed BrdU labeling (injection 5 times at 2 h intervals) at P2, P4 or P6 and analyzed 2 h after the last BrdU injection to label more proliferating cells. To minimize the variation caused by the apical-tobasal gradient of Cre activity, we analyzed the same 200 m length in the apical turn (ϳ1500 m from the most apical tip). There were 5 Ϯ 3 (n ϭ 3) BrdUϩ PCs at P2, 13 Ϯ 2 (n ϭ 3) BrdUϩ PCs at P4, and 5 Ϯ 1 (n ϭ 3) BrdUϩ PCs at P6 (Fig. 5F ), suggesting that proliferation of PCs started at P2, peaked at P4 and declined at P6. Again, all BrdUϩ cells were PCs, estimated based on location.
To confirm that proliferating cells were PCs, we stained for p75 NGFR , which is expressed on the cell surface of PCs and Hensen's cells but not DCs (White et al., 2006) (Fig. 5G) . Prox1
CreER/ϩ ; p27 loxP/loxP ; CAG-EGFPϩ mice were given BrdU 5 times (at 2 h intervals) at P4 and samples were immunostained with p75 NGFR , BrdU and EGFP. The entire cell body was traced with EGFP, making it easy to determine whether p75 NGFR (expressed on the cell surface) and BrdU (expressed in the nucleus) belong to the same cell. All 25 BrdUϩ/EGFPϩ cells analyzed were also p75 NGFR ϩ (Fig.  5GЈ,GЉ) .
We frequently observed pH3ϩ PCs distributed in the HC layer between the inner most row of OHCs and IHCs (Fig. 6 A) . We also found 2 Ϯ 1 (n ϭ 3) pH3ϩ PCs in either metaphase (Fig.  6 B) or anaphase (Fig. 6C) . To determine whether neonatal p27
Kip1 -negative PCs can complete the cell cycle and give rise to new daughter cells, we injected BrdU 5 times (at 2 h intervals) at P2 followed by one EdU injection at P4. We found BrdUϩ/ EdUϩ PCs (Fig. 6 D) , suggesting that p27
Kip1 -PCs incorporated BrdU at P2 generate new daughter cells that were then able to reenter S phase and incorporate EdU at P4. We observed 30 Ϯ 5 (n ϭ 3) BrdUϩ/EdUϩ PCs in each sample. In all samples, there was an increase in the total number of PCs, but not DCs (Fig.  6 E, F ) . Together, our results suggest that deleting p27
Kip1 causes PCs to reenter the cell cycle and generate new daughter cells.
The p27 Kip1 -negative PCs and DCs also maintained expression of Sox2 (Fig. 7A-Aٞ) and Prox1 (Fig. 7B-Bٞ iCreERϩ ; p27 ϩ/ϩ (control group) mice given tamoxifen once at P30; EdU once each at P32, P33, P34; and analyzed at P35. No EdUϩ cells were found inside the organ of Corti of control mice and only a very limited number of EdUϩ/Sox2ϩ cells (4 Ϯ 2, n ϭ 3) (believed to be PCs based on location) were observed in experimental mice (data not shown). This observation verifies that adult PCs have limited proliferative capacity.
Functional consequences due to inducible loss of Sox2 or p27
Kip1 in the mouse cochlea We examined the long-term effect of the conditional loss of Sox2 at P0 and P1, because the most significant cellular proliferation was observed at neonatal ages. We found significant HC loss in cochlear samples of experimental, but not control mice at P16 (Fig. 8 A-C) . The majority of the lost HCs were OHCs (Fig. 8 B, C) , while small fractions were IHCs (Fig. 8 BЈ,  arrow) , which was further confirmed by TUNEL staining (Fig.  8 D-DЈ) . In addition, more HCs were lost in the apical turn than in middle or basal turns (Fig. 8 A-C) . Similarly, we also analyzed the Prox1
CreER/ϩ ; p27 loxP/loxP mice that were given tamoxifen at P0/P1. While all OHCs were intact at P10, sporadic OHC loss was found at P15. TUNELϩ cells were identified at P15, supporting the idea that cell death happened gradually (data not shown).
Our data do not necessarily mean that Sox2 or p27 Kip1 has a direct role in cell survival. We believe that cell death is a secondary effect caused by aberrant cell proliferation in the cochlea which has been observed in other models where deletion of cell cycle inhibitors such as Rb or p19
Ink4d also eventually causes cell death (Chen et al., 2003; Sage et al., 2006; Liu and Zuo, 2008; Yu et al., 2010) . We did not find obvious neuronal phenotypes by P22 by quantifying calbindinϩ spiral ganglion neurons in whole-mount prepared cochlear samples of Fgfr3 iCreERϩ ; Sox2 loxP/loxP that were given tamoxifen at P0 and P1 (data not shown).
Overexpression of Sox2 results in activation of the p27
Kip1 promoter in vitro To provide further evidence that Sox2 can modulate the cisregulatory element of the p27 Kip1 promoter we used a construct in which luciferase is driven by the p27 Kip1 promoter 3.8 kb upstream of its transcription start site (Minami et al., 1997) . We then performed transfections with this construct (Fig. 9A) , along with an internal control of LacZ and either E2F1 (a known positive regulator of the p27 Kip1 promoter (Wang et al., 2005) , Sox2 or an empty vector. Because Sox2 binding has been shown to be dependent on distinct binding partners in different cell types (Kamachi et al., 2000) , we examined the effects of Sox2 overexpression in 3 cell types: MEF cells, HeLa cells, and HEK cells. When transfections were performed on all 3 cell types, we found that overexpression of E2F1 resulted in upregulation of luciferase, as measured by luciferase activity (Fig.  9B-D, n ϭ 3) . Overexpression of Sox2 led to significant upregulation of luciferase in both MEF and HeLa cells (Fig. 9 B, C) , but had no significant effect on HEK cells (Fig.  9D) . Luciferase luminosity was normalized to ␤-galactosidase luminosity to account for any changes due to cell viability, cell number or transfection efficiency. When the p27 Kip1 promoter was removed from the vector, minimal luciferase was observed, with no regulation due to overexpression of Sox2 or E2F1 (Fig. 9B-D,  n ϭ 3) .
Sox2 binds the p27
Kip1 promoter in vitro Activation of the p27
Kip1 -luciferase plasmid by overexpression of Sox2 demonstrates that both Sox2 and p27
Kip1 are potentially in the same pathway, but it is unclear whether it is a direct activation of p27
Kip1 by Sox2 or whether Sox2 is func- tioning indirectly to activate the p27 Kip1 promoter. To distinguish these possibilities, we created 9 primer pairs which contiguously cover ϳ2 kb of the promoter region directly upstream of the luficerase open reading frame (ORF) (Fig. 9E) . Since there are a very limited number of IPCs in the cochlea, we could not measure this interaction in vivo. Instead, we performed ChIP under the same conditions used for the luciferase experiments (Fig.  9B-D) , and observed a significant enrichment of the region ϳ1400bp upstream of the luciferase ORF (amplicon #7) when the Sox2 antibody was used (Fig. 9F , n ϭ 3) . These data are displayed as enrichment over background (2 (Ct Sox2) Ϫ (Ct IgG) ), which is then normalized to the nonspecific amplicon to account for any nonspecific binding of the Sox2 antibody.
The ChIP data presented here, combined with the luciferase reporter assays, and the in vivo epistatic interaction, suggest that Sox2 is able to act in cis to control expression of p27 Kip1 . Such regulation is cell content dependent as it occurs only in IPC but not OPC/DC in vivo, and in MEF/ HeLa but not HEK cells in vitro. However, we cannot rule out the possibility that Sox2 can also regulate p27
Kip1 in an indirect manner.
Discussion
In this study, we demonstrate that Sox2 maintains the quiescent state of neonatal and juvenile IPCs by maintaining p27 Kip1 expression (summarized in Fig. 10 ). In addition, luciferase reporter and Sox2-ChIP assays demonstrate that Sox2 is an activator of the p27 Kip1 promoter and Sox2 can interact with cis-regulatory regions of p27 Kip1 . Our data also show that this signaling cascade occurs in an agedependent manner.
A novel role of Sox2 in neonatal and juvenile cochlear IPCs
Sox2 is a transcription factor that carries a DNA-binding high-mobility group (HMG) domain and affects gene transcription through collaboration with different partners that are specific to cell type or age (Kamachi et al., 2000) . In many mouse embryonic tissues such as the retina, Sox2 is highly expressed in proliferating progenitors and loss of Sox2 leads to defective proliferation (Taranova et al., 2006) . This suggests a general role of Sox2 to promote proliferation in embryonic cells, which might explain the severe defect in inner ear development in the two Sox2 hypomorphic mouse models (Kiernan et al., 2005) .
Sox2 also antagonizes Atoh1, which is a transcription factor crucial for HC development (Dabdoub et al., 2008) . Because Sox2 is highly expressed in postnatal SCs (Hume et al., 2007; Oesterle et al., 2008) , we first hypothesized that Sox2 maintains SC fate and predicted that Sox2 deletion would cause a conversion of SCs into HCs. However, our data do not support this hypothesis and suggest that Sox2 is dispensable for SC fate maintenance.
In contrast, deletion of Sox2 specifically in postnatal cochlear SCs shows that Sox2 keeps neonatal and juvenile IPCs quiescent by maintaining expression of p27 Kip1 . This novel role of Sox2 in regulating its target p27
Kip1 may be important for other tissues and cell types as well. Of note, Sox2-negative/p27
Kip1 ϩ IPCs were present (Figs. 2 B-Bٞ, 3E-Eٞ) . We have 2 speculations: (1) it is Kip1 in vitro. A, Schematic of the luciferase construct used in the reporter assay. The blue region is a 3.8 kb putative p27 kip1 promoter fragment. B-D, The effect of Sox2 overexpression on p27 Kip1 transcriptional activity was measured in MEF (B), HeLa (C), and HEK cells (D) . All values were normalized to the negative control empty vector (EV), then compared with the positive control E2F1, or Sox2 overexpression. Minimal luciferase activity was detected when a promoter-less luciferase vector was used (empty-luc), with no increases occurring in the presence of Sox2 or E2F1. E, Schematic of the p27-luciferase plasmid and amplicon location. F, qPCR data from ChIP experiments performed in MEF cells transfected with p27-luciferase plasmid and Sox2. A significant enrichment of amplicon 7 (ϳ1400 bp upstream of Luciferase ORF) was observed when the Sox2 antibody was used for ChIP. *p Ͻ 0.05. due to the fact that different IPCs require different amounts of time to degrade the endogenous p27
Kip1 present before Sox2 ablation occurred, which would explain the Sox2-negative/ p27
Kip1 ϩ IPCs; (2) it is also possible that Sox2 is one of many factors needed to keep IPCs quiescent, and this heterogeneity underlies our observation.
Our data demonstrate that Sox2 is dispensable for expression of p27
Kip1 in OPCs and DCs. We also did not find Sox2-dependent p27
Kip1 regulation in HEK cells, implying that this cell type does not express the appropriate binding partners needed for Sox2 to regulate p27 Kip1 . Therefore, it is possible that like HEK cells, OPCs, and DCs lack the Sox2-binding partners needed for interaction with p27 Kip1 , whereas IPCs, MEF and HeLa cells retain them, allowing Sox2-dependent p27 Kip1 expression. Alternatively, other Sox family members such as Sox9 (Mak et al., 2009) and Sox10 (Breuskin et al., 2009) loxP/ϩ with Sox2 loxP/ϩ mice. Therefore, it remains to be determined whether Sox2 is required to keep postnatal IPHs quiescent. It is also unclear whether Sox2 is required to maintain quiescence of mouse vestibular SCs. Addressing this issue is difficult because iCre activity of Fgfr3 iCreER was absent in vestibular SCs (data not shown) and is beyond the focus and scope of our study here.
Roles of p27
Kip1 during mouse cochlear development The role of p27 Kip1 in driving cochlear progenitors to exit the cell cycle has been well established (Chen and Segil, 1999; Löwenheim et al., 1999) . By deleting p27
Kip1 in PCs and DCs at P0 and P1, we found that only p27
Kip1 -negative PCs (both IPCs and OPCs) could proliferate, complementary to the study where neonatal cochlear SCs (mostly cells in the lesser epithelial ridge) were targeted by viruses expressing p27 Kip1 -shRNA resulting in proliferation and production of daughter cells (Ono et al., 2009 (Oesterle et al., 2011) . We thought the difference might be explained by the occurrence of CreER leakage (i.e., active Cre without tamoxifen induction) in CAG CreERϩ mice which was reported to occur after the first week (Oesterle et al., 2011) ; thus the proliferative "DCs" might actually be PCs that migrated to region of inner most row of DCs when samples were analyzed at 6 weeks (Oesterle et al., 2011) .
Decline in the proliferative capacity of postnatal cochlear SCs with age Our current study of Sox2 and p27
Kip1 deletion and previous studies of Rb ablation in SCs at different postnatal ages (Yu et al., 2010; Huang et al., 2011) together support that the intrinsic proliferative capacity of postnatal IPCs declines as development proceeds. It is possible that adult SCs, even in the absence of cell cycle inhibitors, lack expression of cell cycle-positive regulators such as cyclin D1. In line with this explanation, neonatal SCs have higher expression of cyclin D1 than adult SCs, and interestingly PCs have higher cyclin D1 expression than DCs at neonatal ages (Laine et al., 2010) . This might explain why p27
Kip1 -negative, neonatal DCs could not proliferate. Furthermore, overexpression of cyclin D1 in adult utricle SCs significantly increased their proliferative capacity in vitro (Loponen et al., 2011) . Cyclin D1 overactivation in adult cochlear SCs may also lead to increased proliferation, but this has not been tested.
Modulation of Sox2 and p27
Kip1 for mammalian hair cell regeneration When HC damage occurs in non-mammalian vertebrates such as birds, fish and amphibians, surrounding SCs proliferate and trans-differentiate into HCs, through which their hearing capacity is recovered. Decreased proliferation of SCs in the Phoenix mutant zebrafish leads to defective HC regeneration (Behra et al., 2009) , which further highlights the importance of SC proliferation. However, in mammals, SCs are strictly kept quiescent even after HC damage, which might account for the inability of mammals to regenerate HCs.
Therefore, driving SCs to proliferate could be a necessary step in restoring the competence of regenerating HCs after damage in mammals. Our data suggest that the development of inhibitors of either Sox2 (for IPCs) or p27 Kip1 (for IPCs and OPCs) would allow neonatal SCs to proliferate and with proper delivery of these inhibitors, such treatment could have specific effects on inner ear cochlear SCs.
In summary, our in vivo epistatic genetic studies reveal that Sox2 can act as an upstream activator of p27 Kip1 and that the Sox2-p27
Kip1 pathway helps to keep neonatal and juvenile IPCs quiescent. Because our current data demonstrate that proliferative PCs keep their intrinsic SC fate, we propose that additional steps (e.g., activation of Atoh1) are needed to direct daughter cells to undergo HC fate commitment and differentiation to achieve hearing regeneration in mammals. Kip1 signaling pathway maintains the quiescent state of inner pillar cells (red). p27
Kip1 itself is needed to keep outer pillar cells (blue) quiescent, whereas the identity of the upstream regulator is unclear. Neither Sox2 nor p27
Kip1 is necessary to maintain the quiescence of Deiters' cells (green).
